Episode Details
Back to Episodes
Novartis's Pelacarsen Misses—What's Next for Rivals? & FDA Approves Etcamah Before Progression
Description
Novartis's pelacarsen missed its cardiovascular endpoint despite lowering Lp(a)—what should Amgen and Lilly rethink? FDA accelerated approval brings AstraZeneca's Etcamah (camizestrant) to ESR1-mutated, HR-positive, HER2-negative advanced breast cancer before progression, with confirmatory benefit still required. Following Monday's CAR-T coverage, new reporting traces Bristol Myers Squibb's notifications to early June, months before public confirmation. Also: Revolution Medicines' Rasonque (daraxonrasib) data in previously treated RAS-mutant lung cancer, and Superluminal's $60 million financing for rare genetic and hypothalamic obesity.
Alex Mercer and Maya Patel host the Daily Roundup for September 4. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.